Klaus Orlinger
VICE PRESIDENT RESEARCH
Sternco Engineers Inc.
Austria
Biography
Hookipa’s vectors are not impeded by vector-neutralizing antibodies and can be administered repeatedly, providing even greater immune protection. Levels of specific T cells generated by TheraT® are unprecedented in the field and have the potential to transform active immune-therapy in cancers. Hookipa’s vectors are not impeded by vector-neutralizing antibodies and can be administered repeatedly, providing even greater immune protection. Levels of specific T cells generated by TheraT® are unprecedented in the field and have the potential to transform active immune-therapy in cancers.
Research Interest
Hookipa’s vectors are not impeded by vector-neutralizing antibodies and can be administered repeatedly, providing even greater immune protection. Levels of specific T cells generated by TheraT® are unprecedented in the field and have the potential to transform active immune-therapy in cancers.
